Compare KNOP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNOP | CHRS |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.2M | 177.7M |
| IPO Year | 2012 | 2014 |
| Metric | KNOP | CHRS |
|---|---|---|
| Price | $11.23 | $1.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $5.51 |
| AVG Volume (30 Days) | 42.7K | ★ 1.0M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.51 | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.00 | $1.09 |
| 52 Week High | $11.78 | $2.62 |
| Indicator | KNOP | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 59.31 | 49.09 |
| Support Level | $10.18 | $1.29 |
| Resistance Level | $11.67 | $1.49 |
| Average True Range (ATR) | 0.39 | 0.07 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 59.09 | 30.56 |
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.